AnaptysBio, Inc.
ANAB
$65.35
$0.630.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 49.61M | 15.11M | -38.63M | -39.33M | -21.78M |
| Total Depreciation and Amortization | 606.00K | 610.00K | 601.00K | 606.00K | 601.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.88M | 30.54M | 27.25M | 25.56M | 23.29M |
| Change in Net Operating Assets | 19.90M | -73.62M | -29.46M | 2.46M | -68.78M |
| Cash from Operations | 98.00M | -27.36M | -40.24M | -10.70M | -66.67M |
| Capital Expenditure | -1.00K | -12.00K | -39.00K | -35.00K | -263.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 73.50M | 103.29M | 36.44M | 14.88M | -29.13M |
| Cash from Investing | 73.50M | 103.28M | 36.40M | 14.85M | -29.40M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.21M | 336.00K | 1.42M | 290.00K | 555.00K |
| Repurchase of Common Stock | -3.38M | -9.72M | -51.10M | -4.42M | -456.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -51.96M | -1.01M | -823.00K | -24.46M | 27.47M |
| Cash from Financing | -43.13M | -10.39M | -50.50M | -28.59M | 27.57M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 128.36M | 65.54M | -54.34M | -24.44M | -68.50M |